Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 897518 | ISIN: US62855J1043 | Ticker-Symbol: MYD
Tradegate
05.06.25 | 10:34
4,580 Euro
-1,29 % -0,060
1-Jahres-Chart
MYRIAD GENETICS INC Chart 1 Jahr
5-Tage-Chart
MYRIAD GENETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,5604,72011:40
4,5604,72011:13

Aktuelle News zur MYRIAD GENETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MYRIAD GENETICS Aktie jetzt für 0€ handeln
DiMyriad Genetics, Inc.: Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen102Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the...
► Artikel lesen
MoMyriad Genetics, Inc.: Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types146SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease...
► Artikel lesen
28.05.Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 20257
27.05.Myriad Genetics, Inc.: Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting6
21.05.Scotiabank cuts Myriad Genetics stock rating, slashes price target8
08.05.What Analysts Are Saying About Myriad Genetics Stock24
07.05.Myriad Genetics, Inc.: Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology5
07.05.MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook21
07.05.Myriad Genetics stock target cut to $5 by Jefferies25
07.05.Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges31
07.05.MYRIAD GENETICS INC - 10-Q, Quarterly Report10
06.05.Myriad Genetics Q1 2025 slides: Revenue declines 3% as company slashes guidance6
06.05.Myriad Genetics Non-GAAP EPS of -$0.03 beats by $0.02, revenue of $196M misses by $4.51M2
06.05.MYRIAD GENETICS INC - 8-K, Current Report2
05.05.Myriad Genetics Q1 2025 Earnings Preview2
05.05.Myriad Genetics' Earnings: A Preview2
30.04.Myriad Genetics, Inc.: Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor4
25.04.Myriad Genetics, Inc.: Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting4
22.04.Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?22
21.04.Myriad Genetics, Inc.: Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing106SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of Clinical...
► Artikel lesen
Seite:  Weiter >>
87 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1